Email updates

Keep up to date with the latest news and content from BMC Medicine and BioMed Central.

Journal App

google play app store
Open Access Highly Accessed Open Badges Review

New treatments for influenza

Sailen Barik

Author Affiliations

Center for Gene Regulation in Health and Disease, Cleveland State University, 2351 Euclid Avenue, Cleveland, Ohio 44115, USA

Department of Biological, Geological and Environmental Sciences, Cleveland State University, 2121 Euclid Avenue, Cleveland, Ohio 44115, USA

BMC Medicine 2012, 10:104  doi:10.1186/1741-7015-10-104

Published: 13 September 2012


Influenza has a long history of causing morbidity and mortality in the human population through routine seasonal spread and global pandemics. The high mutation rate of the RNA genome of the influenza virus, combined with assortment of its multiple genomic segments, promote antigenic diversity and new subtypes, allowing the virus to evade vaccines and become resistant to antiviral drugs. There is thus a continuing need for new anti-influenza therapy using novel targets and creative strategies. In this review, we summarize prospective future therapeutic regimens based on recent molecular and genomic discoveries.

Cathelicidin; defensin; influenza; hemagglutinin; neuraminidase; NSAID; oseltamivir; siRNA; zanamivir